Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan.

In P2a Caucasians, the OSBP decrease was statistically significant at any tested dose of rostafuroxin (Table 3 and Table S5 ) being greater with 50 μg rostafuroxin than with 500 μg rostafuroxin, even though this difference did not reach statistical significance (Table 3 and Table S5 ).

also in 111,027 other papers